Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 6:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 1,863 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Small portion Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

Longitudinal Study to Determine the Effectiveness of the Mobility Checkup for Older Adults

NCT05745402
View directory record Official record
Conditions
Healthy Aging
Interventions
Mobility Checkup for older adults
Behavioral
Lead sponsor
College of St. Scholastica, Inc.
Other
Eligibility
55 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 25, 2026, 6:34 PM EDT
Recruiting Phase 1 Interventional

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

NCT07315113
View directory record Official record
Conditions
EGFR Mutation Positive Non-small Cell Lung Cancer, EGFR Mutated Non-small Cell Lung Cancer Patients
Interventions
NXP900, Osimertinib
Drug
Lead sponsor
Nuvectis Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Calverton, Maryland • Boston, Massachusetts • Eugene, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 25, 2026, 6:34 PM EDT
Completed Not applicable Interventional

MyLife: A Digital Health Coaching Program

NCT03529903
View directory record Official record
Conditions
Lifestyle-related Condition, Obesity, Sedentary Lifestyle, PreDiabetes, Hypertension
Interventions
Health Coaching
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 64 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 25, 2026, 6:34 PM EDT
Withdrawn Phase 1 Interventional

Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC)

NCT07073183
View directory record Official record
Conditions
Squamous NSCLC
Interventions
CV09070101 mRNA vaccine (CVHNLC) 50 µg, CV09070101 mRNA vaccine (CVHNLC) 100 µg, CV09070101 mRNA vaccine (CVHNLC) 200 µg, CV09070101 mRNA vaccine (CVHNLC) 400 µg
Biological
Lead sponsor
CureVac
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Fairfax, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 25, 2026, 6:34 PM EDT
Active, not recruiting Phase 1 Interventional

Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

NCT03993873
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumors, MET Gene Alterations
Interventions
elzovantinib (TPX-0022)
Drug
Lead sponsor
Turning Point Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
12
States / cities
La Jolla, California • Orange, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 25, 2026, 6:34 PM EDT
Completed Not applicable Interventional

Remote Myocardial Ischemic Preconditioning in Humans

NCT00588042
View directory record Official record
Conditions
Coronary Artery Ischemia
Interventions
blood pressure cuff
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 25, 2026, 6:34 PM EDT
Completed Phase 1 Interventional

A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen

NCT01497470
View directory record Official record
Conditions
Cancer
Interventions
Custirsen, paclitaxel and carboplatin
Drug
Lead sponsor
Achieve Life Sciences
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Detroit, Michigan • Dallas, Texas • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2016 · Synced Oct 25, 2026, 6:34 PM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

NCT06593522
View directory record Official record
Conditions
MTAP-deleted NSCLC
Interventions
anvumetostat
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
20
States / cities
Duarte, California • Los Angeles, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 25, 2026, 6:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Brown Adipose Tissue Activation on Insulin Sensitivity in Humans

NCT01791114
View directory record Official record
Conditions
Insulin Sensitivity, Obesity
Interventions
Cold exposure, Cold exposure plus propranolol, Thermoneutral Conditions, Cold water consumption, Tepid water consumption, Exercise, Meal consumption
Other
Lead sponsor
Rutgers University
Other
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Oct 25, 2026, 6:34 PM EDT
Terminated Phase 1 Interventional

A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors

NCT06158958
View directory record Official record
Conditions
Solid Tumors
Interventions
ABBV-303, Budigalimab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
11
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 25, 2026, 6:34 PM EDT
Completed Not applicable Interventional Results available

A Study Promoting Critical Illness Recovery in the Elderly

NCT02963558
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Critical Illness, Critical Care
Interventions
cycle ergometry
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 18, 2024 · Synced Oct 25, 2026, 6:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Stay Active Physical Activity Program

NCT04675658
View directory record Official record
Conditions
Healthy Lifestyle, Sedentary Behavior
Interventions
CBPA + family support, CBPA
Behavioral
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 25, 2026, 6:34 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Adverse Adolescent Pathways to Substance Use

NCT06977178
View directory record Official record
Conditions
Anxiety, Adolescent Development, Substance Use
Interventions
Trier Social Stress Test
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 14 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 25, 2026, 6:34 PM EDT
Completed Early Phase 1 Interventional

Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy

NCT01894451
View directory record Official record
Conditions
Inflammatory Breast Carcinoma
Interventions
89Zr-bevacizumab, FDG-PET/CT, MRI scan, Tumor biopsies
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
21 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 25, 2026, 6:34 PM EDT
Not listed Not applicable Interventional

Utility of 2- Octyl Cyanoacrylate (2-OCA)

NCT05278013
View directory record Official record
Conditions
Ascites, Fluid Loss
Interventions
Dermabond
Other
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years to 100 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Oct 25, 2026, 6:34 PM EDT
Completed Not applicable Interventional Results available

Recording Cutaneous Vagal Nerve Activity With Multi-Electrode Array (MEA) in Patients Undergoing VNS Therapy

NCT06827548
View directory record Official record
Conditions
Vagus Nerve Stimulation
Interventions
Multi-Electrode Array (MEA) Recording
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 25, 2026, 6:34 PM EDT
Completed Not applicable Interventional Results available

InnFocus MicroShunt Versus Trabeculectomy Study

NCT01881425
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Glaucoma Surgery, InnFocus MicroShunt
Procedure · Device
Lead sponsor
InnFocus Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
24
States / cities
Glendale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Oct 25, 2026, 6:34 PM EDT
Completed Phase 3 Interventional Results available

Epidural Anesthesia Within an Enhanced Recovery Pathway in Reducing Pain in Patients Undergoing Gynecologic Surgery

NCT02423876
View directory record Official record
Conditions
Intraoperative Complication, Malignant Female Reproductive System Neoplasm, Pain
Interventions
Epidural analgesia, Intraoperative Complication Management and Prevention, Pain Therapy
Drug · Other · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 25, 2026, 6:34 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

NCT03600883
View directory record Official record
Conditions
KRAS p.G12C Mutant Advanced Solid Tumors
Interventions
sotorasib, Anti PD-1/L1, Midazolam
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
713 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
39
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 25, 2026, 6:34 PM EDT
Completed Not applicable Interventional

Improving Preterm Infant Outcomes With Family Integrated Care and Mobile Technology

NCT03418870
View directory record Official record
Conditions
Premature Birth of Newborn
Interventions
Family Integrated Care
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 33 Weeks
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
6
States / cities
Fresno, California • La Jolla, California • Oakland, California + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 25, 2026, 6:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Carbon-14-Labelled [14C] LOXO-305 (Pirtobrutinib) in Healthy Male Participants

NCT06180954
View directory record Official record
Conditions
Healthy
Interventions
[14C]-LOXO-305, LOXO-305
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 25, 2026, 6:34 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Kidney Stone Surgery (Percutaneous Nephrolithotomy [PCNL])

NCT02384200
View directory record Official record
Conditions
Nephrolithiasis, Urinary Tract Infections
Interventions
nitrofurantoin monohydrate/macrocrystalline capsules, ampicillin, gentamicin, vancomycin, ceftriaxone
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
7
States / cities
Phoenix, Arizona • San Diego, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2019 · Synced Oct 25, 2026, 6:34 PM EDT
Completed Phase 1 Interventional

Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer

NCT01837329
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Tetrathiomolybdate
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 19, 2019 · Synced Oct 25, 2026, 6:34 PM EDT
Withdrawn Phase 2 Interventional

Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

NCT03220009
View directory record Official record
Conditions
Cervical Carcinoma, Esophageal Carcinoma, Mucosal Melanoma, Mucosal Melanoma of the Head and Neck, Oral Cavity Mucosal Melanoma, Recurrent Melanoma, Stage II Vulvar Cancer AJCC v7, Stage III Vulvar Cancer AJCC v7, Stage IIIA Vulvar Cancer AJCC v7, Stage IIIB Vulvar Cancer AJCC v7, Stage IIIC Vulvar Cancer AJCC v7, Stage IV Oral Cavity Cancer AJCC v6 and v7, Stage IV Vulvar Cancer AJCC v7, Stage IVA Oral Cavity Cancer AJCC v6 and v7, Stage IVB Oral Cavity Cancer AJCC v6 and v7, Stage IVC Oral Cavity Cancer AJCC v6 and v7, Vaginal Carcinoma
Interventions
Conventional Surgery, Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Patient Observation, Radiation Therapy
Procedure · Biological · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 25, 2026, 6:34 PM EDT